With a background in chemical engineering and biochemistry Christopher I. Halliday counsels clients on strategic intellectual property (IP) issues in pharmaceutical, biotechnology, chemical, medical devices, and food science areas. He prepares and prosecutes patent applications related to new chemical entities, pharmaceutical formulations, and biologics as well as implantable medical devices, chemical processes and catalysts. Clients turn to Christopher for IP litigation advice and to develop opinions involving infringement, validity, and freedom to operate.
Clients also request Christopher’s assistance in the course of mergers or acquisitions, and negotiating licenses, transfer agreements, and assignments.
Before joining Morgan Lewis, Christopher was employed by a Philadelphia-area IP boutique law firm as an associate. He has also worked at SmithKlineBeecham Pharmaceuticals (now GlaxoSmithKline), the New Hampshire Office of the Attorney General, and the New Hampshire Office of the Public Defender. Christopher has represented many indigent clients in the New Hampshire courts.
Before entering private practice, Christopher worked for corporate, nonprofit, and government organizations.
Established and implemented intellectual property programs for many small, midsize, and multinational companies in the life sciences, technology and financial services sectors
Represented a prominent national university in actions in the Eastern District of Pennsylvania and the Western District of Tennessee regarding alleged breaches of material transfer agreements and patent infringement relating to client's cancer treatment
Represented a major university in connection with multiple federal court litigations concerning intellectual property disputes arising out of cancer research programs
Represented SPI Pharma in Roquette Freres v. SPI Pharma in support of successful defense in patent litigation matter
Represented Adolor Corporation in connection with its exclusive worldwide collaboration with Pfizer
Represented Enzon, Inc. in its acquisition of the North American rights to Abelcet, an antifungal used to treat patients with invasive fungal infections related to cancer, organ transplantation and other conditions
Represented multiple technology and life sciences companies in sales to publicly traded and other strategic buyers
Represented Foresight Biotherapeutics, Inc. in implementation of an IP program, and acquisition of Foresight by Shire.
Represented Acura Pharmaceuticals in its exclusive license, development and commercialization agreement for North America with King Pharmaceuticals for opioid analgesic products utilizing Acura's patented Aversion® (abuse deterrent) Technology platform -
Represented Specialty pharmaceutical company in its negotiation with large U.S. pharmaceutical company for the promotion by the U.S. company of the specialty pharmaceutical’s product
Represented a startup company in spin-out license and technology acquisition from a large pharmaceutical company
Represented Merck KGaA in its $850 million up-front and up to $2 billion in milestone payments agreement to co-develop and co-commercialize its anti-PD-L1 antibody with Pfizer as a potential treatment for multiple tumor types
Represented Auxilium Pharmaceuticals in its collaboration with Actelion for the development and commercialization of Xiaflex® in Canada, Mexico, Brazil, and Australia
Represented ViroPharma in its global collaboration and licensing agreement for the subcutaneous combination of Cinryze® (C1 esterase inhibitor [human]) with Halozyme Therapeutics' recombinant human hyaluronidase enzyme (rHuPH20) EnhanzeTM technology
Represented Auxilium Pharmaceuticals in its up to $262 million development, commercialization, and supply collaboration with Asahi Kasei for Xiaflex® in Japan
Represented GlaxoSmithKline in its up to $1.58 billion antisense drug collaboration with Isis Pharmaceuticals for the development and commercialization of therapeutics for rare and infectious diseases
Franklin Pierce Law Center, 1999, J.D.
Pennsylvania State University, 1996, B.S.
Temple University, Beasley School of Law, 2002, LL.M.